Member Info for Saxondale

Fast track status too - wheels are moving

At least that investor can have his own £1 party , when his 3 shares are worth that lol

Apologies , that comment may have sounded a bit cynical . I have put money on them now , and given the progress with new sites and deals , I think the risk of this ever failing is much reduced , and the chance of great success is steadily increasing.

Have been in and out here over the years . Back in this morning .
This will re-rate one day , and when it does , the last thing I want be doing is not holding any shares .
As always with Hummingbird , hope for the best but expect the worst .
Hoping now too for some Dugbe news pre Christmas

Had a reply yesterday after i emailed the REMAP-CAP team , asking about when their update on the Immunology domain may come .
The Immune Modulation domain originally had these treatments included :

•No immune modulation for COVID-19(no placebo)
•interferon-beta-1a(IFN-ß1a)
•anakinra (interleukin-1receptor antagonist;IL1Ra)
•tocilizumab (IL-6 receptor antagonist;IL6Ra)
•sarilumab(IL-6 receptor antagonist; IL6Ra)

Reply stated that they had some preliminary data published on tocilizumab on 19th Nov , but they hoped to publish their full analysis before Christmas .

So maybe we will get to see some Interferon data soon if their analysis covers the whole domain .

Happy with this , and big respect to the guy for relinquishing the reins to someone more capable of moving the company into the major league . Guy has the right set of skills to get us there . Onwards and Upwards

Exactly M300 , ahead of the curve . Right at the sharp end , they have the know how and the capability of staying ahead too .

Good health & festive cheer to you Roy and all others holding here . I think you hit the nail on the head about taking some perspective .
Having some other shares that have been like rockets and roller coasters recently , you can sometimes put unfair expectations and your own timelines onto a company , when in reality they are doing the best they can , and often far more than we know about .

Roy , yes I agree that blaming the WHO is pointless , and that I don't have all the facts . I also understand that trialing existing therapies would save a lot of time in having something already produced on the shelf to go with .
We are also on REMAP , which of the two big trials I am glad we are still actively involved with , as the steroid issue is fully contained ( as it would not have been with Solidarity )
We also have our own trial , which unfortunately still seems hung up due to regulatory/ funding arrangements .

So my feelings are just of frustration . I have the same frustration with SNG , who in regard to Interferon , seem even more ignored whilst the euphoria of vaccine successes soak up all the oxygen . At least with SNG they capitalised on the Phase 2 with that £80 million placing - so nobody else to blame if it fails , and I am much very happy with that .

Similarly here , we have such a small share float , that another £14-20 million placing would not bother me one bit . But I don't see it happening . Markku seems against further dilution .

But Clevegen news is just around the corner - what that will throw up who knows - perhaps some partnership deals and large injection of funds . But could they siphon some of that off to further Traumakine studies ? I don't think that would be popular , as if Clevegen is a goer , all cash should be used to bring that to market .

I just wonder if Hibiscus is on ice until they get a REMAP update . It could change the whole scenario ( for good or bad ) and save whoever a lot of money on another stand alone trial .

Exciting times ahead for this share soon - which is about time as compared to my other shares this month this has been like watching Dulux dry .

https://patents.justia.com/patent/10247730

This was published in June 2020 - to highlight how different the injected and I/V route are , and how injected is not going to cut the mustard . yet despite this , the WHO soldiered on recruiting thousands of candidates and injecting them with Interferon .
Faron have stated multiple times that timing is crucial , as is the necessity of delivering it through I/V .
They even patented a method of monitoring the patients CD73 expression in order to decide on dosing .

https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5

I'm just a private investor with no scientific credentials , yet I know all this .
The WHO , and the worlds scientists in charge of sorting out some sort of solution to this crisis however , don't appear to .
Go figure ?

I managed to get a few at 38.9 on the bell . Not that I needed any more , but might as well have some fun while they play around . I've yet to guess a date , but I'm sensing things are starting to come to a head .

Very touching . Thank you for sharing .

Good to know they are adding , great confidence . Ignore short term SP drops and even the small rises . Thats pharma shares . Just hold these now and enjoy the next few months , by Feb or March these will be worth alot more I'm sure .

some good volume on the Nas and 6% up . people anticipating some good news soon perhaps

Not sure why this presentation deserves an RNS ( rather than RNS Reach ) , unless I missed a yet undisclosed detail .
Either way - more confidence in the Clevegen studies - every discovery confirms their enthusiasm .
Part II 87% recruited ( across 10 cohorts ) -so thats encouraging - some must already be complete.

Dr. Markku Jalkanen, Faron's CEO, said: "Our growing understanding of how the tumour microenvironment shields a cancer from the immune system and fuels its growth makes it a clear target for the next generation of immunotherapies. Everything we are learning about bexmarilimab from its rapidly advancing development programme across a broad range of cancer types gives us continued confidence in the potential of this anti-Clever-1 antibody to activate the immune system and remove T cell exhaustion."

4.2Moz equivalent - not a bad start , only gonna get bigger and bigger . And bulk mining confirmed.

The patent protects Faron for using IFN Beta1a in I/V delivery to treat ARDS and other vascular diseases .
Blurb -
The patent further protects Faron's final FP-1201-lyo (lyophilised interferon-beta or Traumakine®) formulation for the intravenous treatment of acute respiratory distress syndrome ("ARDS") and other vascular diseases.

The more I think about the WHO Solidarity trial , the more I believe that the direction many of these trials have taken this year ( and not just concerning us ) , have been directed and controlled by the powers of Big Pharma .
Its just how the world works . If you were a multi billion dollar company , with influence , your plate is going to be at the front of the queue . If your IFN Beta treatment ( Merck ) has a slight chance of getting some positive result - the ensuing profits will be gargantuan . Surely , you would use all your influence to make sure a minor player with a possibly more effective delivery would be kept out of the race until you had secured a winning position .
Why else do we see repeated trials for Remdesivir , Hydroxychloroquine etc .

The good news ( for the likes of us and SNG ) is that now the big boys have used this year tying up trial space with their repurposed therapies , and come up short , the smaller guys will now finally get their chance .

The cases , despite vaccines , will keep rising , in my opinion for years across the globe .

Its a real shame we didn't get included and verified this year , but at least it has given us a chance to build up manufacturing know how and capacity etc .

Nice - just the start :-)

If it gets use intravenously , I would say it will be us . We have the patent for it and have donated to the WHO study .
Like in REMAP though , the actual Interferon could be Rebif or whatever written on the packet ( as in the US , Rebif is readily available ) , but any results from a study based on I/V delivery is our domain .
Slightly disappointed that they still have injected as part of the study . The total results will not give a clear data set as the two delivery methods are crucially different - so not sure what the aim is ?